MILWAUKEE, Aug. 23, 2024 /PRNewswire/ — Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings.
Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Cyclo Therapeutics stockholders will receive only a certain number of shares of Class B common stock of Rafael Holdings, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings at its cash value combined with the value of its marketable securities and certain other investments less certain current liabilities. The transaction agreement unreasonably limits competing transactions for Cyclo Therapeutics by imposing a significant penalty if Cyclo Therapeutics accepts a competing bid. Cyclo Therapeutics insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Cyclo Therapeutics’ board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Cyclo Therapeutics common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/cyclo-therapeutics-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
